Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019; 25(11): 1289-1306 [PMID: 30918424 DOI: 10.3748/wjg.v25.i11.1289]
Corresponding Author of This Article
Jeong Won Lee, MD, PhD, Associate Professor, Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, 25, Simgok-ro 100 beon-gil, Seo-gu, Incheon 22711, South Korea. jwlee223@ish.ac.kr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 21, 2019; 25(11): 1289-1306 Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1289
Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma
Sang Mi Lee, Hong Soo Kim, Sangheun Lee, Jeong Won Lee
Sang Mi Lee, Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Chungcheongnam-do 31151, South Korea
Hong Soo Kim, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Chungcheongnam-do 31151, South Korea
Sangheun Lee, Division of Hepatology, Department of Internal medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea
Sangheun Lee, Institute for Health and Life Science, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea
Jeong Won Lee, Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review, drafting, revision, editing of the paper, and approval of the final version.
Supported bythe Soonchunhyang University Research Fund.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jeong Won Lee, MD, PhD, Associate Professor, Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, 25, Simgok-ro 100 beon-gil, Seo-gu, Incheon 22711, South Korea. jwlee223@ish.ac.kr
Telephone: +82-32-2902975 Fax: +82-32-2903128
Received: January 24, 2019 Peer-review started: January 24, 2019 First decision: February 21, 2019 Revised: February 25, 2019 Accepted: March 1, 2019 Article in press: March 1, 2019 Published online: March 21, 2019 Processing time: 55 Days and 4.7 Hours
Abstract
Hepatocellular carcinoma (HCC) is one of major causes of cancer mortality worldwide. For decades, 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been widely used for staging, predicting prognosis, and detecting cancer recurrence in various types of malignant diseases. Due to low sensitivity of FDG PET for detecting intrahepatic HCC lesions, the clinical value of FDG PET in HCC patients has been limited. However, recent studies with diverse analytic methods have shown that FDG PET has promising role in aiding management of HCC patients. In this review, we will discuss the clinical role of FDG PET for staging, predicting prognosis, and evaluating treatment response in HCC. Further, we will focus on recent clinical studies regarding implication of volumetric FDG PET parameters, the significance of FDG uptake in HCC for selecting treatment and predicting treatment response, and the use of radiomics of FDG PET in HCC.
Core tip: Because of low sensitivity, clinical use of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been limited in patients with hepatocellular carcinoma (HCC). However, recent studies have shown clinical significance of FDG PET in various ways. The objective of this review is to provide an overview of the current literature regarding FDG PET in HCC and discuss emerging role of FDG PET in aiding management of HCC patients.
